PH patients N [%] age [years ± SD] 62 ± 13 min 23 max  73 gender [n/%]   male  6 [35]  female 11 [65] Body-Mass-Index [kg/m2] 26.7 ± 5.9        min 15 1 max  34.2 WHO Functional Class [n]   1 --- 2 6[35] 3 11[65] 4 --- Cardiac Catheterization   mPAP [mm Hg] 40.8 ± 15.7 PVR [dyn*s*cm -5] 7 ± 3.8 CI [L * min -1 * m-2] 2.7 ± 0.6 RAP [mm Hg] 6 ± 3 Medication [n]   ERA 8 PDE5i 5 Prostanoids [inh.] 2 investigational product (riociguat) 2 monotherapy 12[71] combination therapy 5[29]

Table 1: Baseline characteristics of the study population. PH: Pulmonary Hypertension; WHO: World Health Organisation; mPAP: mean Pulmonary Artery Pressure; PVR: Pulmonary Vascular Resistance; CI: Cardiac Index; RAP: Right Atrial Pressure; ERA: Endothelin Receptor Antagonist; PDE5i: Phosphodiesterase-5- Inhibitor; values are mean ± SD.